Alcoholic Liver Disease from the Clinical Point of View by Sevastianos, Vassilios A. & Dourakis, Spyros P.
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A b s t r A c t
Liver disease is responsible for more than 55% of deaths resulting from alcohol abuse, 
while the prevalence of alcoholic liver disease (ALD) is closely correlated with per 
capita alcohol consumption. ALD represents a wide range of histological changes 
ranging from simple steatosis to heavier forms of liver injury including alcoholic hepa-
titis (AH), cirrhosis and/or the concurrent development of hepatocellular carcinoma. 
These alterations of the hepatic parenchyma do not necessary reflect distinct stages of 
the liver disease progression, but rather a continuum relating to histological changes 
that may be observed simultaneously in the same patient. The fact that only 35% of 
patients with heavy alcohol abuse develop advanced stages of liver disease, suggests 
that in the pathogenesis of ALD several other factors are involved that include gen-
der, obesity, drinking patterns, dietary factors, non-sex-linked genetic factors and 
smoking. Also, long-term drinking can affect the non-alcoholic fatty liver disease and 
other hepatic disorders, such as hemochromatosis, synergistically with hepatitis B or C 
and/or with the human immunodeficiency virus. The diagnosis of ALD is based on a 
combination of findings, including the history of significant alcohol consumption, the 
clinical evidence of the concomitant liver injury and the support of the clinical case 
from the resultant histological, imaging and laboratory findings. The beneficial effect 
of the AH treatment with corticosteroids occurs in patients with encephalopathy or 
with poor prognosis based on the various grading and prognostic systems of gravity, 
while the harmful effect is prominent in patients with milder disease, as they manifest 
an increased risk of infections compared with those not receiving corticosteroids. In 
patients with alcoholic hepatitis that cannot take corticosteroids for various reasons 
and in those with the onset of functional renal failure (“hepatorenal syndrome”), use 
of pentoxifylline is recommended.
1 .  I n t r o d u c t I o n
Humans have been drinking alcoholic beverages at least since the Neolithic period. 
For more than 10,000 years, beverages which have undergone alcoholic fermentation 
(alcohol concentration of less than 16%) represent for the Western civilization a source 
of fluids and energy, particularly during those periods when drinking water from na-
ture was unsafe, while the boiling water practice had not yet prevailed. However, the 
morbidity of the alcohol use or abuse sharply rose when the production of wine and 
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distilled spirits received a wide acceptance in Europe, around 
the sixteenth century AD.1
Alcoholic liver disease (ALD) represents the oldest form of 
liver damage known to humans.2 It includes a broad spectrum 
of liver parenchyma lesions ranging from simple steatosis to 
severe cirrhosis and hepatocellular carcinoma. Alcohol abuse 
represents a significant background for morbidity development 
from organic systems or organs other than the liver that are 
often co-expressed in the same patient.1,3 Today alcohol toxicity 
ranks as the third most frequent cause of morbidity and mor-
tality, from a potentially preventable and socially acceptable 
harmful agent. It accounts for 3.8% of deaths worldwide and 
4.6% of disability-adjusted life years cases (DALYs).4 Recent 
data from the CDC and the US Prevention indicate that 80,000 
Americans died between 2001 and 2005 because of alcohol 
abuse. Interestingly, these deaths and the non-fatal disease 
impacts of alcohol consumption drained significant resources 
from every economy, that was more than $ 257 million in 2006, 
in the case of US economy.1
Thus, since liver disease and other complications related 
to alcohol consumption are entirely consequences of human 
behavior, any intervention aimed to inform and the raising 
awareness of the nature and risks of abuse is imperative, ben-
eficial and can yield significant scientific and social benefits.
2 .  e p I d e m I o l o g y
The actual prevalence of ALD is tough to assess in the 
general population. Recently, with the use of liver elastography 
as a screening tool, alcohol emerged as an underlying cause 
for a third of the cases with advanced hepatic fibrosis in the 
general population.5
It seems that liver disease is responsible for more than 55% 
of deaths from alcohol abuse while the prevalence of ALD ap-
pears closely correlated with per capita alcohol consumption1. 
It is estimated that for every one-liter-increase in per capita 
use of alcohol, the incidence of cirrhosis grew by 14% in men 
and by 8% in women.6
The highest prevalence of alcoholic liver disease in Europe 
has been recorded in the United Kingdom in parallel with the 
eastern and southern European countries. More accurately, 
in half of the European countries including Austria, France, 
Germany, Italy, Portugal, and Spain, as well as in two Eastern 
European countries (Romania and Hungary), a sharp decline 
in mortality from alcoholic cirrhosis has been observed in the 
recent years. By contrast, in Western European countries 
such as Finland, Ireland, the United Kingdom and in most 
Eastern European countries including Estonia, Poland and 
Russia, the mortality rate from cirrhosis followed a continuous 
upward trend, as did the percentage of patients who required 
hospital care. It is interesting that the largest differences in 
consumption among these countries are more pronounced at 
ages over 45 years while the incidence is two to three times 
higher in men than women.4,7 However, a study that included 
13,000 Danish women showed a greater chance of develop-
ing cirrhosis compared with males for a given consumption 
of ethyl alcohol.8
However, the published epidemiological evidence of 
alcoholic disease in Europe probably underestimates the 
actual burden of the problem. Data from the European Liver 
Transplant Registry indicate that the number of transplants 
due to alcoholic disease today follow an increasing trend. At 
the same time, alcohol abuse is the second leading cause for 
liver transplantation and in one-third of cirrhosis cases, it has 
led to transplantation in the European continent.9
There are significant differences in the prevalence and the 
mortality associated with ALD between different ethnological 
groups. Countries with large Muslim communities have lower 
alcohol consumption rates and ALD. In the United States, al-
cohol consumption per capita is 7.5 to 9.9 liters per person per 
year and the ALD displays intermediate prevalence between 
of what is observed in the countries with the lowest and those 
with the highest consumption rates.1 Indeed, the maximum 
mortality rate from alcoholic cirrhosis has been recorded 
among white Hispanic, followed by non-Hispanic black, white 
non-Hispanics and Hispanics blacks. In women, the correlation 
is scaled by the largest percentage in non-Hispanic black, and 
then the white Spanish-speaking, white non-Hispanic and at 
the end of Spanish-speaking black.10 Therefore, the literature 
data show differences in alcohol consumption among different 
ethnological or social groups.11 However, it remains unclear 
whether the differences in the percentage of alcoholic cirrhosis 
and ALD recorded, represent genetic peculiarities, differences 
in the amount and type of alcohol consumed or characteristics 
of socioeconomic status and accessibility of medical services 
in each country.
Despite the strong association between alcohol consump-
tion and the incidence of liver disease, severe alcohol liver 
disease develops in only a small minority of patients with 
abuse. In the Dionysus study, the possibility alcohol-related 
liver toxicity was significant with the consumption of more 
than 30 gr per day, while those who consumed more than 120 
gr experienced cirrhosis more frequently. However, only 2.2% 
of the high-risk individuals had liver cirrhosis in this study,12 
which underlines the idiosyncratic nature of the liver damage 
or the presence of differences of other nature in the alcohol 
receptiveness.
On the other hand, mortality from liver cirrhosis in France 
between 1925 and 1964 was estimated at 14 per 100,000 indi-
viduals who consumed less than 80 gr of alcohol per day and 
357 per 100,000 among those who drank more than 160 gr per 
day. It seems, therefore, that those who consume between 80 
and 160 gr of alcohol a day bear a significant risk of develop-
ing progressive liver disease including alcoholic hepatitis and 
cirrhosis.1,13 But in a more recent meta-analysis, an increased 
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likelihood of loss of life from liver cirrhosis was found among 
men - women who consumed between 12 and 24 gr alcohol 
daily.14
Therefore, it is shown that there is probably a lower limit 
on alcohol consumption, beyond which the risk of development 
and progression of liver disease is significant.14 This thresh-
old is probably very low and probably difficult to document 
because of the difficulties to record in the general population 
consumptions from 10-12 gr of alcohol per day.4 However, the 
effects of binge drinking on the organism in general are still 
unknown (drinking five or more drinks for men and four or 
more for women).15
3 .  n A t u r A l  h I s t o r y  o F  A l c o h o l I c 
l I v e r  d I s e A s e  A n d  r I s K  F A c t o r s
ALD represents a broad variety of disorders, ranging from 
simple steatosis to more severe liver injury including alcoholic 
hepatitis (AH), cirrhosis, or the parallel development of hepa-
tocellular carcinoma (HCC).16 These lesions of the hepatic 
parenchyma do not necessarily reflect distinct stages of liver 
disease progression, but rather involve a continuous spectrum 
of parenchymal changes that can be observed simultaneously 
in the same patient (Figure 1).17 Indeed, the advanced stages 
of progression of the liver disease associated with the presence 
of more specific histological findings include Mallory bodies, 
megamitochondria or perivenular and perisinusoidal fibrosis.18
Fatty liver characterizes an early organ response to 
alcohol hit observed in more than 90% of the heavy abuse, 
with the presence of mild hepatocyte steatosis in the zone 3 
(perivenular). It can also affect the respective 2 or even the 
zone 1 (periportal) in the cases with more significant liver 
damage. Interestingly, only one-third of people with severe 
abuse develop more severe forms of ALD such as advanced 
fibrosis and cirrhosis. In patients with underlying ALD and 
heavy alcohol consumption one can observe, at the clinical 
level, recurrent episodes of alcoholic hepatitis (AH) that 
can lead to the development of portal hypertension and liver 
failure with high rates of short-term mortality.16
The fact that only 35% of patients with severe alcohol 
abuse develop advanced stages of liver disease, rather suggests 
that in the pathogenesis of ALD some other factors are also 
involved (Table 1, 2).16 Several risk factors have been identi-
fied, and these include gender, obesity, the drinking patterns, 
dietary factors, non-sex-linked genetic factors, and smoking. 
Female gender is one of the well-documented bear for the 
ALD development, which can be attributed to the lower levels 
of alcoholic dehydrogenase in the gastric fluids, the higher 
percentage of body fat and the presence of estrogen which 
characterizes female gender. Obesity is another important 
factor that accelerates the development of both fibrosis and 
cirrhosis. Experimental studies show that the synergistic ef-
fects of obesity and alcohol abuse include among others the 
response of endoplasmic reticulum system to stress, the type I 
macrophage activation and the resistance to adiponectin.3,16,19,20
FIgure 1. Natural history of alcoholic liver disease.12,22,25,28,37
Table 1. Risk factors for the development of alcoholic 
related cirrhosis.22
• Men >60-80gr/d
• Woman >20gr/d
Every day use
Alcohol outside meals
Binge drinking
No wine
Female gender 
Race 
Concurrent viral hepatitis (hepatitis C)
HIV infection
Increased body weight and insulin resistance 
Smoking 
Hemochromatosis
Genetic factors
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Daily or almost daily heavy drinking which starts at an 
early age increases the risk of serious ALD development 
compared with episodic or binge drinking. Some genetic 
factors appear to influence the development of ALD, but 
currently little data are available in the literature. Changes 
in the genes encoding antioxidant enzymes, cytokines, other 
inflammatory mediators and enzymes that metabolize alcohol 
may play a role in pathogenesis.20 Indeed, recent studies show 
that changes in polymorphism of TNF-238A21 and PNPLA3 
protein (patatin-like phospholipase domain-containing protein 
3)22 may influence the development of alcoholic cirrhosis in 
white patients who abuse alcohol, but these data require more 
literature documentation.
Also, long-term drinking can interfere synergistically with 
viral hepatitis B or C and human immunodeficiency virus, the 
non-alcoholic fatty liver disease and disorders such as hemo-
chromatosis that accelerate the progression of liver disease at 
more advanced stages probably through activation of multiple 
mechanisms.16,23 Specifically, it appears that patients with 
hepatitis C who consume more than 30-50 gr of alcohol per 
day have a four-fold increased risk of developing liver fibrosis 
while those who drink excessive alcohol have 30 times greater 
risk of developing cirrhosis.4
On the other hand, the presence of iron in the liver biopsy 
specimens has also been associated with the development of 
fibrosis in ALD, and with increased mortality in alcoholic cir-
Table 2. Genes involved in the development of alcoholic related cirrhosis.22
Genes involved in alcohol metabolism
ADH1B
ADH1C
CYP2E1
CYP1A1
ALDH2
Conflicting results for all variants; data from meta-analysis suggested 
no association with ALD
Genes related to oxidative stress
GSTM1
GSTP1
GSTT1
MnSOD
NAT
HFE
Mostly negative studies; positive associations challenged by failure to 
replicate in subsequent studies; MnSOD variation may be associated 
with hepatocellular carcinoma (to be confirmed indecently 
Genes implicated in immune reactions
TNFa
Interleukin (IL)-10
IL-1R
IL-1b
CD14 receptor
CTLA-4
TLR-4
All conflicting or yet unconfirmed except for TNFa-238A allele 
which was found to be associated with ALD in several independent 
studies and by meta-analysis; and CD14 variation which was linked 
to ALD in three studies
Genes coding for fibrosis associated factors
TGFb1
MMP3
No association in sufficiently powered genetic case-control studies
Genes involved in the modulation of steatosis
PPARg
MTP
ApoE
Yet unconfirmed single studies of PPARg and MTP variants with low 
sample sizes showing significant association with ALD; ApoE with 
conflicting data from two very small studies 
Miscellaneous
NFkB1
DRD2
SLC6A4
Single study showing association of NFkB1 variant 94 ins/del with 
fibrosis; DRD2 and SLC6A4 negative
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rhosis. Elevated levels of iron in serum is not uncommon in 
patients with ALD compared with alcoholics without underly-
ing liver disease. However, while there are studies which have 
described a liver disease correlation with the mutation H63D, 
there is not a respective definite correlation with mutations in 
C282Y HFE gene. Of course, alcohol and iron may act syn-
ergistically to produce oxidative stress and thus to accelerate 
the progressive liver damage.24
4 .  d I A g n o s I s  o F  A l d
The diagnosis of ALD is based on a combination of find-
ings, including the history of significant alcohol consumption 
and the evidence of the related liver injury. Furthermore, the 
clinical suspicion may support the corresponding histologi-
cal, imaging and laboratory findings. Alcohol abuse is usually 
denied by patients while semiological features of abuse are 
present. Physicians often underestimate the problem with the 
result, not rarely seen, alcohol abuse to be revealed as reality 
by the consequences and complications.25
Both clinical and laboratory findings of ALD may be 
non-diagnostic, especially in patients with mild ALD or early 
stages of alcoholic cirrhosis. Therefore, the clinician should 
be sensitized in detecting ALD resorting to the search for spe-
cific information from other family members or even through 
questionnaires combined with the laboratory evidence that can 
support the clinical suspicion.
4 . 1 .  c l I n I c A l  p I c t u r e
The findings on physical examination in ALD patients 
vary considerably and have low sensitivity, even in detecting 
advanced disease or cirrhosis. Although particular clinical find-
ings are observed more frequently among people with ALD, 
such as swelling of the parotid, the contraction of the palmar 
fascia and signs of male feminizing, however, even those are 
not specific3. On the other hand, the detection of hepatic 
encephalopathy, dilated veins in the anterior abdominal wall, 
ascites, presence of spider nevi and the feeling of weakness 
have been associated with an increased risk of life loss during 
the next year.26
Alcoholic hepatitis is manifested clinically by anorexia, 
fever, and jaundice. On physical examination one may find 
tender hepatomegaly (due to deposition of fat and protein in 
hepatocytes),27 relatively small spleen enlargement (the op-
posite happens in cirrhosis on the grounds of hepatitis), ascites 
and loss of proximal muscle mass. Hepatic encephalopathy and 
renal failure of functional type (“hepatorenal syndrome”) can 
coexist.28 In the right hypochondrium, there is often (50%) an 
audible murmur (suggesting enhanced hepatic arterial perfu-
sion). Indeed, in a reference study including 101 patients with 
alcoholic hepatitis, the murmur was verified in 58% of the 
patients.29 The fever (38-38,5 °C) could be attributed to the 
alcoholic disease after ruling out the presence of infection that 
often coexists.28 The clinical picture of alcoholic hepatitis mim-
ics an acute cholecystitis with fever, jaundice, and leukocytosis 
added on a preexisted hepatomegaly.25
The simultaneous presence of fever and lymphocytosis can 
mislead the clinician towards the septic syndrome, especially if 
the patient’s history is unclear. On the other hand, malnutri-
tion and comorbidities often coexist in the same patient with 
an advanced liver disease, predisposing to the development 
of infections, and imposing, at least, the necessity of taking 
blood and urine cultures, obtaining a chest radiograph, and 
evaluating the ascitic fluid, if present.30
Also, one can often observe unexplained intrahepatic and 
extrahepatic cholestasis due to the obstruction of the lower 
third of the bile duct from fibrosis due to the accompanying 
chronic pancreatitis.25 This finding should be evaluated care-
fully on the basis that if endoscopic retrograde cholangiopan-
creatography (ERCP) is performed in these cases, it incurs 
a significant risk for the development of severe necrotizing 
pancreatitis and, therefore, it should not be carried out for 
purely diagnostic reasons.30
It is worth noting that the clinician must take into ac-
count that ALD often coexists with manifestations from other 
organs or systems including malnutrition and muscle mass 
loss, alcoholic cardiomyopathy, pancreatic dysfunction and 
neurotoxicity from alcohol abuse.3
4 . 2 .  l A b o r A t o r y  F I n d I n g s
Currently, there is no specific biological marker to associ-
ate alcohol with the underlying cause of liver damage. Several 
laboratory parameters used in clinical practice have been 
linked with chronic alcohol use and alcoholic liver damage. 
Indeed, the sensitivity of carbohydrate-deficient transferrin 
(CDT) and γGT to evaluate the drinking of greater than 50gr 
per day is 69% and 73%, respectively. These rates are signifi-
cantly higher than that of AST (50%), ALT (35% ) and MCV 
(52%),31 while the combination of CDT and γGT shows much 
greater sensitivity, reaching near 90% (Figure 2).32
γGT is usually higher in ALD patients compared to those 
who suffer from other liver diseases. Given the lower cost of 
the assay, it remains the laboratory test most commonly used 
in clinical practice. However, 1/3 of individuals with heavy 
alcohol use have γGT values within the normal limits  in serum, 
even in cases of excessive consumption.33 Additionally, the 
γGT serum activity loses its sensitivity in more advanced liver 
disease because the activity is often found increased in patients 
with extensive fibrosis, regardless of the underlying etiology. 
Recently it was found that the γGT levels in serum are affected 
not only by the amount of alcohol consumed but also by body 
mass index and gender.34 Lower γGT levels <100 IU/L or the 
ratio of total bilirubin/γGT >1 have been proposed as predic-
tors of increased mortality rates within one year in patients 
with alcoholic cirrhosis.35 Also, direct metabolites of alcohol 
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have been studied and used as biological markers of abuse, 
such as the determination of ethyl glucuronide (EtG) show-
ing sensitivity and specificity of 92% and 91% respectively.36
Alcoholic hepatitis is characterized by increased ami-
notransferase (transaminase) greater than twice the upper 
limit of normal (>2XULN), but it always remains <300 
U/L, with the ratio of AST (aspartate aminotransferase or 
glutamic oxaloacetic transaminase SGOT) to ALT (alanine 
aminotransferase or glutamic pyruvate transaminase SGPT) 
is typically >2 in more than 70% of cases.25,28,36,37 The above 
typical picture is attributed to a lack of pyridoxine (vitamin 
6) that is a cofactor for the ALT enzyme activity and to the 
increased mitochondrial AST.
ALT levels >500 U/L exclude the diagnosis of alcoholic 
hepatitis. Higher values should raise the suspicion of, concur-
rent with alcohol abuse, viral, ischemic or drug-related (e.g., 
by taking a relatively large amount of paracetamol) hepatitis. 
Attention is needed in the interpretation of the increases in 
serum transaminases levels owing to an extrahepatic origin 
(rhabdomyolysis, myocardial infarction, etc.).
While the above mentioned may coexist, increasing IgA, 
leukocytosis with neutrophilia (maybe at levels of leukemoid 
reaction: >50.000/mm3), increased C-reactive protein (CRP), 
and hyperbilirubinemia (>5 mg/dl) with predominance of the 
direct type, can also be present. The latter typically increases 
more with the coexistence of renal failure or hemolytic ane-
mia. Note that γGT is often found significantly increased 
(70%) due to its activation. Also, macrocytosis (MCV >100fl) 
may be observed owing to the absence of B12 and folate 
deficiencies, alcohol toxicity on maturating erythrocytes and 
impaired lipids on the membranes of erythrocytes (red cells 
“as spurs” - spur-cell). Often thrombocytopenia is present 
because of bone marrow suppression from ethanol toxicity 
or sequestration of platelets in the splenic reservoir due to 
portal hypertension and splenomegaly (hypersplenism). There 
may be a prolongation of prothrombin time because of liver 
failure that cannot correct despite the parenteral adminis-
tration of vitamin K. Also, often hyperuricemia coexists (in 
severe hepatic impairment shows hypouricemia) as well as 
hypokalemia of multifactorial etiology (vomiting, but mostly 
from the toxic effect of ethanol on urinary tubules). Serum 
ferritin can increase, consequential to its release from the 
hepatocytes because of inflammation but also related to the 
extent of liver fibrosis.25,28,37 The ferritin levels in the serum 
are normalized after a few months of abstinence from alcohol 
and the improvement of inflammatory activity in the liver.38 
Erythrocyte sedimentation rate and serum CRP levels can 
increase because of the presence of polyclonal hypergam-
maglobulinemia typically seen in chronic liver disease. The 
serological markers of hepatotropic viral infections and the 
absence of autoantibodies could exclude concurrent viral or 
autoimmune liver diseases. Autoantibodies (antinuclear and 
against smooth muscle fibers) are often found in low titers 
(<1/160), but not accompanied by a significant increase of 
gamma globulins. If higher serum titers of these autoanti-
bodies or hypergammaglobulinemia are found, histological 
examination is essential for establishing the diagnosis and 
the marginalization of coexisting autoimmune liver disease.
An increase in creatinine >1.5 mg/dl and the reduction of 
the creatinine clearance <40ml/min are indications of hepa-
torenal syndrome representing an adverse prognostic marker 
for the disease progression. However, in cirrhotic patients, 
creatinine and urea in serum underestimate the severity of 
the renal impairment. The latter may be attributed to the 
presence of hyperbilirubinemia (technical problems in the 
biochemical measurement), to the blood volume increase due 
to the concomitant dilution, to the hypo-protein feeding, and 
the reduced urea synthesis from a dysfunctional liver paren-
chyma. Furthermore, a significant role may be assigned to the 
malnutrition typically observed in these individuals with the 
parallel decrease in muscle mass and consequent endogenous 
creatinine decline production. Because of the above, a much 
greater reduction is required in glomerular filtration rate for 
the corresponding increase in urea and creatinine to become 
apparent. In contrast, the increase in blood urea could be at-
tributable to gastrointestinal bleeding, to intense catabolism 
or corticosteroids intake.25,28,37
4 . 3 .  I m A g I n g  s t u d I e s
Imaging studies provide valuable information. Ultrasound, 
CT, and MRI can be used as tools for the presymptomatic de-
tection of fatty liver, but do not contribute to the determination 
of the exact etiology of the underlying liver disease. However, 
they can support decisively the exclusion of other causes of 
the impaired liver biochemistry such as the obstructive biliary 
lesions or the presence of invasive liver neoplasms.3,4
The liver ultrasound usually shows diffuse echogenic 
liver parenchyma. The infiltration of the liver parenchyma 
with fat reduces hepatic attenuation compared with spleen 
on non-contrast imaging. Indeed, in the CT study of the liver 
FIgure 2. Sensitivity of biochemical markers to detect severe 
alcohol abuse.32
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without intravenous contrast, the liver appears enlarged and 
hypodense in contrast to the corresponding picture of the 
spleen and kidney, while intrahepatic branches of portal and 
hepatic veins are most conspicuous than that of the healthy 
liver. The findings are like those observed in non-alcoholic 
fatty liver disease/steatohepatitis (NAFLD/NASH). Focal fat 
concentration in the liver parenchyma presents on CT imaging 
as hypodense area (“pseudo-tumor’’) and may be confused 
with certain liver tumors while for the differential diagnosis an 
MRI must performed. The findings as mentioned earlier could 
coexist with that of liver cirrhosis (irregularity of the external 
contour of the liver, enlarged caudate lobe, thickening of the 
gallbladder wall, ascites, splenomegaly, portosystemic shunts). 
An additional Doppler ultrasound study shows an increase 
in the speed of hepatic artery blood flow or an increase in its 
diameter.25,28,37
Among these methods, ultrasound probably has the low-
est sensitivity and specificity, particularly when steatosis on 
histologic level does not exceed the limit of 20-30% of the 
hepatic parenchyma. MRI and MR spectroscopy are reliable 
tools for assessing the degree of steatosis, but the lack of 
standardization of these methods and their high costs limit 
their use and availability.4
4 . 4 .  t h e  p o s I t I o n  o F  t h e  t r A n s I e n t 
e l A s t o g r A p h y  I n  A l d
Measuring liver stiffness appears to be a valuable tool for 
the assessment of hepatic fibrosis also in patients with ALD. 
However, in studies that did not consider the coexistence of 
alcoholic steatohepatitis, the lower value of the stiffness index 
corresponding to F3 and F4 fibrosis stage in histological level 
was significantly higher compared to that verified in patients 
with viral related liver diseases. Also, several studies have 
shown that patients with alcoholic cirrhosis had significantly 
higher stiffness values compared to those who suffered from 
cirrhosis secondary to viral infection, underscoring the fact 
that the causative agent can greatly affect the extent and the 
progression of fibrosis in the liver.4
Therefore, the liver stiffness index can be correlated with 
the stage of fibrosis in ALD, but the diagnosis of advanced-
stage liver disease, severe fibrosis or cirrhosis, probably 
requires a higher lower limit of the index as compared with 
other liver diseases. Increased liver stiffness index can also be 
observed in cases of alcoholic disease and concomitant increase 
of aminotransferase levels above 100 IU/L, but in these cases, it 
should be interpreted with great caution.39 Possibly the differ-
ent distribution of fibrosis in the liver and the cholestasis, the 
liver enlargement, the inflammation, and hepatocytes necrosis 
as the result of acute hepatocellular injury could give a satisfac-
tory explanation of this phenomenon.40 Thus, heavy alcohol 
abusers with or without the presence of alcoholic hepatitis 
can experience an increase liver stiffness index leading to an 
inaccurate estimate of fibrosis, a datum that should be noticed 
by the clinical hepatologist, as the liver stiffness index in ALD 
has not yet been standardized.
4 . 5 .  l I v e r  h I s t o l o g y  I n  A l d
Although liver biopsy does not significantly contribute to 
the management of patients with ALD, in some cases it is use-
ful, considering that more than 20% of patients with a history 
of alcohol abuse have a secondary or other coexisting cause of 
liver damage. Also, on a well-compensated liver disease, the 
biopsy can capture the stage and the severity of liver disease.3
Alcoholic liver disease is associated with three main 
histological lesions in the liver that often coexist (steatosis, 
steatohepatitis, cirrhosis). A total of 80% of patients with 
alcohol abuse present histologically liposis, 10-35% steato-
hepatitis and 10% cirrhosis. On hematoxylin-eosin staining, 
many hepatocytes are foamed with fat droplets in the proto-
plasm and vacuolar nucleus displaced to the cell membrane. 
The lesions are most pronounced around portal spaces (zone 
1 of the hepatic lobules). The droplets of fat are stained with 
oil red O in cryostat sections. During the fixation of the liver 
biopsy specimens, in a formalin solution, the fat droplets dis-
solve and thus are shown as empty areas within hepatocytes. 
Also, liposis in the liver parenchyma, is expressed as ballooning 
degeneration of the hepatocytes, containing the nucleus near 
amorphous eosinophilic Mallory bodies, with the presence 
of giant mitochondria, but one can also see an infiltration of 
parenchyma by polymorphonuclear neutrophils. The degree 
of polymorphonuclear cell infiltration has a poor predictive 
value and can coexist with mononuclear cells. There is typical 
presence of pericentral (around the central vein, in zone 3 of 
the hepatic lobules) and perisinusoidal fibrosis (in the space of 
Disse). Fibrosis can extend in the portal areas or other central 
vessels forming central-central and central portal bridges. 
Fibrosis represents the result of connective tissue production 
by cells of Ito (stellate cells) and may be followed by the ac-
cumulation of material, like the composition of the basement 
membrane of capillaries, culminating in the capitalization of 
sinusoidal in the case of micro-nodular liver cirrhosis. The his-
tological features of NASH may be identical to those observed 
in alcoholic hepatitis.25,28,37
4 . 6 .  d I F F e r e n t I A l  d I A g n o s I s
Diagnosis is based on clinical presentation (jaundice, as-
cites, tender hepatomegaly, increased transaminase <300U/L, 
the ratio AST/ALT >2, leukocytosis with polymorphonucle-
ates) in an individual with alcohol abuse. In some cases, you 
may need an interaction with family members or the working 
environment to confirm the abuse. Histology studies may be 
useful for prognostic purpose, but are not necessary for the 
diagnosis.
Differential diagnosis includes NAFLD/NASH, acute or 
chronic viral hepatitis, acute drug-induced hepatitis, fulminant 
Wilson disease, autoimmune hepatitis, acute cholecystitis, 
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hepatic abscess, and hepatocellular carcinoma. Caution is also 
needed in the differential diagnosis of the liver manifestations 
of the alcoholic cardiomyopathy that can exist or co-exist with 
alcoholic hepatitis/cirrhosis. The differential diagnosis of the 
ethanol withdrawal syndrome by hepatic encephalopathy 
complicating alcoholic hepatitis is of great importance for 
treatment management while based primarily on semiology 
of the sympathetic system stimulation. Alcoholic hepatitis is a 
febrile illness with concomitant leukocytosis with polymorpho-
nucleates elevation, in parallel with an increase in CRP levels 
and needs a careful differential diagnosis of possibly concur-
rent bacterial infections that may worsen with the therapeutic 
management (corticosteroids).25,28,37 It has been suggested that 
procalcitonin in the serum that rises in infections but not in 
alcoholic hepatitis could help in the differential diagnosis.41
5 .  A l d  p r o g n o s I s
The prognosis depends primarily on the patient’s decision 
to stop alcohol use. However, avoiding alcohol use is often 
manifested by a temporary worsening of the clinical condi-
tion despite the abstinence. Patients with alcoholic hepatitis 
exhibit a mortality rate of 40% even with the best treatment. 
Poor prognostic factors include leukocytosis, severe fibrosis, 
ascites, encephalopathy, functional renal failure (“hepatorenal 
syndrome”) and coagulopathy. In most patients with less severe 
forms of alcoholic hepatitis who abstain from alcohol use, we 
can see a clinical and laboratory improvement in a few months
There have been proposed various systems for the assess-
ment of alcoholic hepatitis clinical severity [Maddrey index, 
Glasgow score, MELD (Model for End-stage Liver Disease), 
Lille model score] to select the appropriate patients who may 
benefit from treatment with corticosteroids (Table 4 and 5). 
These systems include common parameters (bilirubin, pro-
thrombin time). The known prognostic classification score 
Child-Turcotte-Pugh used for staging the severity of cirrhosis 
is not accurate for alcoholic hepatitis.
The Maddrey discriminant function (4,6 X prolongation 
of prothrombin time in seconds + bilirubin in mg/dl) is the 
oldest and most widely used. Although it includes the meas-
urement of prothrombin time in seconds compared to the 
control but not the INR (International Normalized Ratio) that 
is the modern way of evaluation internationally (was devised 
to standardize the results among laboratories). The survival 
in those with Maddrey index <32, is about 90%, so the side 
effects of using steroids exceed the expected benefit from the 
treatment intervention.
The Glasgow alcoholic hepatitis score (not to be confused 
with the Glasgow coma scale) is based on five parameters: age, 
white blood cells, urea, bilirubin and prothrombin time (Table 
3). The score helps in predicting and distinguishing those with 
Maddrey index patients >32 who will benefit most from the 
use of corticosteroids. Glasgow score value >9 correlated with 
poor prognosis in 1 and three months. Those who had Maddrey 
index >32 and Glasgow score >9 but received corticosteroids 
had three-month survival 60% versus 40% of those on only 
conservative treatment.
The MELD score [3.8 [10log serum bilirubin (mg / dL)] + 
11.2 [10log INR] + 9.6 [10log serum creatinine (mg/dL)] + 
6.4, www.mayoclinic.org/meld/mayomodel7.htm, www.unos.
org/resources/MeldPeldCalculator.asp?index=98] is a statis-
tical model used to predict survival in patients with cirrhosis 
while on the waiting list for a liver transplantation in the US. 
Several studies showed that the MELD score is as good or bet-
ter than Maddrey score for assessing the severity of alcoholic 
hepatitis. Scores >11 are associated with increased mortality 
Table 3. Glasgow scoring system.25,28,37
Grade
1 2 3
Age <50 ≥50 -
WCC (109/L) <15 ≥15 -
Urea (mmol/L) <5 >5 -
INR <1,5 1,5-2 >2,0
Bilirubin (μmol/L) <125 125-250 >250
Table 5. Prognostic systems for three-month survival in 
alcoholic hepatitis.25,28,37
Markers Mortality 
Hepatic encephalopathy >50% at 3 months
Maddrey score >35% at 2 months when >32
MELD score >50% at 3 months when >25
Table 4. Prognostic systems of short-term survival in 
alcoholic hepatitis.25,28,37
Grades  28-day survival
Maddrey score
< 32 93%
>32 68%
Glascow alcoholic  
hepatitis score 
<9 87%
>9 46%
Model for end stage liver 
disease (MELD) score
<11 96%
>11 45%
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from alcoholic hepatitis and value >21 with a 3-month mor-
tality rate of 20%, and puts the indication for corticosteroid 
therapy. Additionally, the score could be assessed during the 
patient’s hospital admission and after one week to determine 
the prognosis.
The Lille score (www.lillemodel.com), considers six 
variables: bilirubin, creatinine, prothrombin time in INR, 
age, albumin and bilirubin change as a response to one-week 
corticosteroid treatment. If there is no response to treatment, 
corticosteroids can be stopped since they are outweighed by 
their potential side effects (particularly infections).25,28,37
In a study from the 2nd University Department of Medi-
cine, University of Athens, including 34 patients with alcoholic 
hepatitis, the total mortality at 30 and 90 days was 6% and 
15% respectively. The accuracy of predicting survival was 
confirmed by models Maddrey and MELD. Also, the AST 
levels, fibrin split products (FSR) and CRP values in serum 
showed a significant correlation with the survival.42
Alcoholic hepatitis represents a poor prognostic factor in 
patients with cirrhosis, because when it coexists in the same 
patient, the total annual mortality rate is 26% compared to 
7% in cirrhosis without steatohepatitis.25,28,37
6 .  t r e A t m e n t
Immediate cessation of alcohol use is recommended with 
the support of the family, the social service and the specialized 
psychiatrist. Complete cessation of alcohol leads to regression 
of fatty infiltration (in 4-6 weeks), inflammation and possibly 
connective tissue that had developed, which is crucial for 
reducing the portal system pressure.
The role of corticosteroids in the treatment of alcoholic 
hepatitis was controversial for a long time. The beneficial ef-
fect manifested in the groups of patients with severe disease, 
namely in patients with encephalopathy or poor prognosis per 
different scoring systems of severity. On the other hand, the 
deleterious effect is significant in patients with milder disease, 
as they exhibit an increased risk of infection compared to pa-
tients how do not receive corticosteroids. A recent systematic 
review yielded an overall negative result but was positive for 
the use of corticosteroids for those with Maddrey score >32 
or hepatic encephalopathy. It is now accepted in patients 
with alcoholic hepatitis, and hepatic encephalopathy, when 
Maddrey index is >32 or the MELD score >21, to administer 
corticosteroids (prednisolone 40 mg/day for four weeks) if the 
patient does not exhibit gastrointestinal bleeding or infection. 
Corticosteroids should not apply to patients with Maddrey 
index <32 or MELD <21. Patients who experience a decrease 
in bilirubin levels after 6-9 days of treatment show significant 
and sustained response in parallel with a good prognosis. The 
mortality rate in the group of patients who have not demon-
strated a drop-in bilirubin levels in the same period was 36.8% 
and 57.9% at 28 and 56 days while those who achieved a bili-
rubin decline by 25%, the corresponding mortality rate was 
0 and 11.1%. Up to 40% of patients with alcoholic hepatitis 
do not respond to treatment with corticosteroids. One must 
treat five patients to save only one. Lille score >0.45 indicates 
non-response to corticosteroids resulting in six-month survival 
<25%. Prednisolone is preferred because it does not need to 
metabolize in the liver, as prednisone does. In patients with 
pancreatitis, gastrointestinal bleeding or renal impairment, 
corticosteroid use has not been studied. The risk of infections 
development during steroid treatment is critical, and close 
clinical monitoring is required.
The increased disposal price of anti-TNF-a compounds 
in patients with alcoholic hepatitis led medical community to 
the use of pentoxifylline. Pentoxifylline is an anti-TNF agent 
but may act through another mechanism because it does 
not change the levels of the cytokines. It is administered as 
Tarontal®, in tablets, per os, at a dose of 400mg, three times 
daily for 28 days. It is recommended for patients that cannot 
take steroids and in patients with functional renal failure event 
(“hepatorenal syndrome”). In patients who did not respond to 
corticosteroids, pentoxifylline administration was not helpful. 
The concomitant use of corticosteroids and pentoxifylline does 
not increase the effectiveness of the intervention.
Initially, alcohol use was considered a contraindication for 
liver transplantation. But in patients who develop end-stage 
liver failure, it can be attempted after a complete abstinence 
from ethanol use for at least six months. During this time, 
some patients will have died, while others will delist. Thus, 
those who have not improved within three months of stopping 
alcohol use, are not expected to improve later, and can be 
considered potential transplantation candidates. Recurrence 
of abuse after transplantation is frequent (10.8%). It is neces-
sary to treat alcoholic disease complications such as ethanol 
withdrawal syndrome, gastrointestinal bleeding, infections, 
ascites or hepatic encephalopathy.
In patients with ascites one can grant unsalted diet and 
diuretics, in those with hepatic encephalopathy lactulose and 
antibiotics against endogenous gut flora (rifaximin) but cases 
with hepatorenal syndrome will need albumin and terlipres-
sin. Also, one can administer H2 receptors antagonists or 
proton pump inhibitors for preventing upper gastrointestinal 
bleeding.
Usually, patients with ALD are cachectic in a hypercata-
bolic condition which worsens the prognosis. Good nutrition 
is essential. In anorectic patients, enteral feeding can be 
administered with 2000 Kcal/day, with an albumin content of 
1.5 gr/kg even in those with hepatic encephalopathy events. 
Survival can be similar to that observed with corticosteroid 
treatment. One can also administer B complex vitamins (be-
fore the administration of carbohydrates to prevent Korsakoff 
syndrome) and folic acid (to address possible shortcomings).
Patients with alcoholic hepatitis exhibit susceptibility to 
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infections, since their polymorphonuclear cells are numer-
ous but functionally inferior. Patients should frequently be 
examined for the presence of bacterial infection (pneumonia, 
spontaneous bacterial peritonitis, urinary tract infection) with 
the appropriate investigations (blood cultures, urine, ascites 
fluid, chest X-ray).
In patients with severe liver disease and withdrawal 
syndrome, chlormethiazole (Hemineurin® or Distaneurin®), 
midazolam (Dormicum®) or lorazepam (Tavor®) can be ad-
ministered due to a shorter half-time. When psychotic mani-
festations prevail, neuroleptic drugs should be administered 
(haloperidol or “atypical” as olanzapine, etc.). The long-term 
administration of baclofen can help without clinically signifi-
cant adverse effects.25,28,37,43
7 .  t h e  r o l e  o F  l I v e r 
t r A n s p l A n t A t I o n  I n  t h e 
t r e A t m e n t  o F  A l d
After a long period of reluctance to add patients with ALD 
to the liver transplant list, a worldwide view is currently formed 
that transplantation offers an excellent survival advantage in 
appropriately selected patients, like that observed for other 
liver transplant indications. The different vision mainly exists 
since the ALD is a self-inflicted disease, in parallel with the 
increased likelihood of significant damage with alcohol use 
to organs other than the liver. Furthermore, in the medical 
community there dominates the lack of compliance of these 
patients to the instructions in the postoperative period, and 
the recurrence of abuse that can lead to early graft failure.44,45
The first primary liver transplant experience in patients 
with alcoholic cirrhosis started in Pittsburgh wherein survival 
among 42 transplanted patients was like in other forms of liver 
disease.46 Similar data have also currently been published by 
other centers. Indeed, the relative survival of patient and graft in 
another study that included 123 patients was 84% and 81% for 
the first year, 72% and 66% for the fifth and 63% and 59% for 
the seventh year after transplantation respectively.47 Without 
liver transplantation five-year survival appears less than 23%.48
Clinicians who treat patients with end-stage liver disease 
due to alcohol abuse, contribute decisively to the success of 
transplantation when they promptly examine this possibility 
as a potential option and refer these patients for evaluation at 
the appropriate transplant centers. A period of six months of 
abstinence from alcohol is widely used to prevent recurrence 
while allowing recovery of the hepatic parenchyma by the 
toxicity of abuse. However, this time-limit cannot be used to 
distinguish the group of patients who will continue to abstain3. 
In a study including 40 patients with ALD admitted to assess 
the likelihood of liver transplantation, it was found that 38% 
had a positive urine test for alcohol and 30% for illicit drugs.49
However, according to a French study, 26 patients with 
alcoholic hepatitis with a high risk of life loss underwent liver 
transplantation after failure to respond to the conservative 
treatment. Patients were selected by the existence of a real so-
cial supportive environment, no previous episodes of alcoholic 
liver disease and non-history of severe psychiatric illness. These 
patients were compared with 26 patients who were randomized 
as the control group. The cumulative percentage of six-month 
survival was significantly higher in the transplanted patients (77 
compared to 23%). The two-year survival was also significantly 
higher (71 compared with 23%). Three of the patients who 
underwent transplantation exposed themselves again to the 
use of alcohol, one 720 days, one 740 days and one 1140 days 
after liver transplantation.50
In conclusion, liver transplantation represents an alterna-
tive for treating selected patients with alcoholic liver disease, 
even though both transplantation from cadaveric and much 
more from a living liver donor raise important social and 
ethical questions.
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